Basic and clinical studies on cefetamet pivoxil

Yuei Irabu, Hiroshi Fukuhara, Hiroaki Nakamura, Hiroshi Kaneshima, Katsuyoshi Shimoji, Keizo Kitsukawa, Yoshiteru Shigeno, Atsushi Saito, Shinko Taira, Isamu Nakasone, Nobuchika Kusano, Seitetsu Hokama

Research output: Contribution to journalArticlepeer-review


We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin, with the following results. 1) Antimicrobial activity : the minimum inhibitory concentrations (MICs) of cefetamet (CEMT) against 338 clinically isolated strains were determined and compared with those of cefteram, cefixime, cefaclor, cefotiam, ampicillin, using a Dynatech MIC-2000 system. CEMT had wide-spectrum antimicrobial activity against these isolated strains, except Pseudomonas aeruginosa, methicillin sensitive Staphylococcus aureus and methicillin resistant S. aureus. 2) Clinical efficacy : CEMT-PI at 500 or 1,000 mg/day was given to 2 patients with bacterial pneumonia, 2 with bacterial pneumonia complicated with chronic bronchitis, 5 with chronic bronchitis and 1 with diffuse panbronchiolitis for 4-14 days. Clinical response was excellent in 2 patients, good in 6, fair in 1 and poor in 1, and the overall clinical efficacy was 80%. 3) Bacteriological efficacy : one strain of Haemophilus influenzae was eradicated, one strain of Klebsiella pneumoniae changed to Proteus vulgaris, and one strain of Streptococcus pneumoniae persisted. 4) Safety : no side effects and altered laboratory findings were observed.

Original languageEnglish
Pages (from-to)193-197
Number of pages5
Publication statusPublished - 1990
Externally publishedYes


  • Cefetamet pivoxil

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies on cefetamet pivoxil'. Together they form a unique fingerprint.

Cite this